Pacira BioSciences, Inc.NASDAQ: PCRX

Pacira BioSciences Announces Top-line Results from Phase 3 STRIDE Study Evaluating EXPAREL as a Lower Extremity Nerve Block

· Issued by Pacira BioSciences, Inc.

On 6ix: 6ix.com/news/pacira-biosciences-announces-top-line-results-from-phase-3-stride-study-evaluating

Watch Pacira BioSciences' latest callPacira Biosciences (NASDAQ:PCRX) Q2 2026 Earnings Call · Replay · Aug 4Read the transcript of Pacira Biosciences (NASDAQ:PCRX) Q2 2026 Earnings Call

-- Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl --

-- EXPAREL achieves highly statistically significant reductions in pain and total opioid consumption from 24 to 96 hours versus bupivacaine HCl (p

Pacira BioSciences, Inc. on 6ix

Earlier from Pacira BioSciences

Later from Pacira BioSciences

All Pacira BioSciences news releases